A biosimilar manufacturer must verify that its product is similar enough to the reference product to serve as an alternative. Comparative quality, efficacy and safety studies are required, which must be carried out in a phased manner to demonstrate biosimilarity.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
